Skip to main content
Clinical Trials/NL-OMON24347
NL-OMON24347
Not yet recruiting
Not Applicable

Exploring bleeding risk and platelet function combined with multiple omics techniques in 22q11.2 deletion syndrome

one0 sites60 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
one
Enrollment
60
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
one

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • \-16 years or older.
  • \-signed informed consent.
  • Adults with 22q11\.2DS
  • \-molecularly confirmed 22q11\.2 deletion syndrome.
  • \-Mentally competent (ability to give informed consent) and aged 16 years and older or, in case the individual is mentally incompetent aged 16 years and older, consent will be given by the legally authorized representative of the subject.

Exclusion Criteria

  • \-The presence of any malignancy.
  • \-Use of antiplatelet or anticoagulant drugs within the last two weeks prior to the study.
  • \-Use of anti\-inflammatory drugs within the last two weeks prior to the study.
  • \- Medical history of auto\-immune thrombocytopenia
  • Specific for healthy controls:
  • \-A medical history of thrombocytopenia (\<150\.000 platelets per mL).
  • \-Increased bleeding risk, defined as a diagnosed bleeding disorder.
  • \-Metabolic disorder.

Outcomes

Primary Outcomes

Not specified

Similar Trials